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Association Between Plasma Neutrophil Gelatinase-Associated
Lipocalin and Cardiac Disease Hospitalizations and Deaths in Older
Women
James J. H. Chong, PhD, FRACP, MBBS; Richard L. Prince, BSc, MB ChB, MD, FRACP, MRCP; Peter L. Thompson, AM, MBBS, MD, FRACP,
FACP, FACC, MBA; Sujitha Thavapalachandran, MBBS, FRACP; Esther Ooi, BSc (Hons), PhD; Amanda Devine, PhD, BAppSc, GradDipEd,
BEd (Hons); E. E. M. Lim, MBBS, FRACP, FRCPA, MAACB; Elizabeth Byrnes, BAppSc, Grad Dip Ed, MAACB, MLabMed; Germaine Wong,
MBBS, PhD, FRACP; Wai H. Lim, MBBS, PhD, FRACP; Joshua R. Lewis, BSc (Hons), PhD

Background-—Neutrophil gelatinase-associated lipocalin (NGAL) or lipocalin 2 may promote atherosclerosis and plaque instability
leading to increased risk of cardiac events. We investigated the relationships between plasma NGAL, cardiovascular disease
biomarkers, and long-term cardiac events.
Methods and Results-—The study population consisted of 1131 ambulant older white women (mean age 75 years) without clinical
coronary heart disease (CHD) and measures of plasma NGAL in the Perth Longitudinal Study of Ageing Women with 14.5-year CHD
and heart failure hospitalizations or death (events) captured using linked records. Over 14.5 years, 256 women had CHD events,
while 118 had heart failure events. Per SD increase in log-transformed NGAL there was a 35% to 37% increase in relative hazards
for CHD and heart failure events in unadjusted analyses, which remained signiﬁcant after adjustment for conventional risk factors
for CHD events (hazard ratio 1.29, 95% CI 1.13–1.48, P<0.001) but not heart failure (P>0.05). Women in the highest 2 quartiles of
NGAL had higher relative hazards for CHD events compared with women in the lowest quartile hazard ratio 1.61, 95% CI 1.08–
2.39, P=0.019 and hazard ratio 1.97, 95% CI 1.33–3.93, P=0.001, respectively. These associations were independent of highsensitivity cardiac troponin I, homocysteine, and estimated renal function. NGAL correctly reclassiﬁed 1 in 4 women who sustained
a CHD event up in risk and 1 in 10 women without CHD events down in risk.
Downloaded from http://ahajournals.org by on January 14, 2019

Conclusions-—NGAL was associated with increased risk of long-term CHD events, independent of conventional risk factors and
biomarkers. These ﬁndings provide mechanistic insight into the role of NGAL with cardiac events. ( J Am Heart Assoc. 2019;8:
e011028. DOI: 10.1161/JAHA.118.011028)
Key Words: coronary heart disease • elderly • lipocalin 2 • myocyte necrosis • neutrophil gelatinase-associated lipocalin

A

n increasing number of inﬂammation-related proteins are
being assessed as biomarkers of coronary artery disease
(CAD) progression and risk prediction. The data from recent
studies point to neutrophil gelatinase-associated lipocalin
(NGAL) as a previously underappreciated factor in CAD
development and progression. NGAL belongs to the lipocalin
superfamily, proteins that specialized in binding and transporting small hydrophobic molecules, and exists in 3 molecular

forms in blood and urine: a monomer, a homodimer, and a
heterodimer, covalently bound with matrix metalloproteinase9. NGAL is highly expressed in kidney tubule cells in response to
injury and hence, a known marker of acute kidney injury. Recent
evidence from both mouse and human studies demonstrates
that NGAL is highly expressed in cardiomyocytes and
atherosclerotic plaques.1–4 In these sites, NGAL modulates a
range of cellular responses, such as proliferation,
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What Is New?
• Neutrophil gelatinase-associated lipocalin is a recently
identiﬁed marker of inﬂammation.
• Older women with elevated neutrophil gelatinase-associated
lipocalin levels had a higher risk of coronary heart disease
hospitalization and death, independent of conventional risk
factors and other cardiac biomarkers.

What Are the Clinical Implications?
• This association between elevated neutrophil gelatinaseassociated lipocalin and coronary heart disease events was
in addition to cardiac troponin I levels and may represent a
future risk stratiﬁcation tool to identify older patients with
atypical symptoms who will beneﬁt most from invasive
coronary angiography.

Downloaded from http://ahajournals.org by on January 14, 2019

differentiation, and apoptosis1 associated with vascular function and atherosclerosis5 and also in vascular remodeling.6,7
NGAL has also been found to be associated with obesity in
humans, in particular, cholesterol mobilization to peripheral
tissues.8 Studies of animal diet–induced obesity suggest that
NGAL may be an important marker of inﬂammation leading to
endothelial dysfunction and elevated blood pressure.9
To investigate these relationships further, we analyzed the
predictive role of NGAL on clinical outcomes in a large cohort
study of older women. In addition, to better understand the
potential pathophysiological role of plasma NGAL in cardiovascular disease, we studied the relationship between NGAL
and high-sensitivity cardiac troponin I (hs-cTnI) , a validated
marker of acute coronary syndrome and mortality previously
studied in this and other populations.10,11 Second, given the
evidence that elevated homocysteine promotes inﬂammatory
monocyte differentiation, activates pro-inﬂammatory pathways, and accelerates the progression of atherosclerosis,12
we also investigated this potential pathological pathway.

were obtained from all participants. Human ethics approval
for the use of linked data for the project was provided by
the Human Research Ethics Committee of the
Western Australian Department of Health, project number
#2009/24.

Study Population
The participants were recruited in 1998 to a 5-year
prospective, randomized, controlled trial of oral calcium
supplements to prevent osteoporotic fractures, the CAIFOS
(Calcium Intake Fracture Outcome) study as described
previously.14 Brieﬂy, 1500 women were recruited from the
Western Australian general population by mail using the
electoral roll. All participants were ambulant with an
expected survival beyond 5 years and were not receiving
any medication (including hormone replacement therapy)
known to affect bone metabolism. Baseline disease burden,
cardiovascular disease risk, and medications were comparable between these participants and the general population of
similar age, although these participants were more likely to
be from higher socioeconomic groups.14 At the conclusion of
CAIFOS, participants were subsequently included in additional follow-up studies for an additional 10 years as the
Perth Longitudinal Study of Aging in Women (PLSAW)
http://www.lsaw.com.au. The randomized controlled trial
was commenced and completed before the introduction of
clinical trial registries; hence the trial was retrospectively
registered in the Australian New Zealand Clinical Trials
Registry ACTRN12615000750583.

Baseline Risk Factors
Baseline medical history including the presence of diabetes
mellitus, hypertension, smoking history (current smokers/
former smokers or nonsmokers), and medications was
obtained from all participants as described previously.11

Biochemistry

Methods
The data, analytic methods, and study materials will be made
available to other researchers for purposes of reproducing the
results or replicating the procedure. This material will be
available on request and approval at the Perth Longitudinal
Study of Ageing Women website.13

Ethics Statement
The Human Ethics Committee of the University of Western
Australia approved the study and written informed consents
DOI: 10.1161/JAHA.118.011028

Venous blood samples were collected between 0830 and
1030 hours after overnight fasting at baseline (1998) and
were stored at 80°C until assessment. Total cholesterol,
high-density lipoprotein cholesterol (HDLC), and triglyceride
concentrations were determined using a Hitachi 917 auto
analyzer (Roche Diagnostics). Low-density lipoprotein cholesterol was calculated using Friedewald’s method.15 hs-cTnI was
measured in 2013 in baseline serum stored at 80°C using
the Abbott ARCHITECT i2000SR STAT hs-TnI assay as
described previously.11 Plasma that had not been previously
defrosted was used to measure NGAL using a 2-step
chemiluminescent microparticle monoclonal immunoassay
Journal of the American Heart Association
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Figure 1. Overview of the study participants. All participants had hospital (1980–2013) and mortality
(1998–2013) records available from the Western Australian Data linkage system. CAD indicates coronary
artery disease.
Downloaded from http://ahajournals.org by on January 14, 2019

on an automated platform (Abbott Diagnostics, Longford,
Ireland). The interassay coefﬁcient of variation over a 3-week
period was 6.07% and 2.63% at concentrations of 21 and
1194 ng/L, respectively. Baseline creatinine was measured
using an isotope dilution mass spectrometry traceable Jaffe
kinetic assay in 2003 on a Hitachi 917 analyzer (Roche
Diagnostics GmbH, Mannheim Germany). Estimated glomerular ﬁltration rate (eGFR) using creatinine was calculated using
the Chronic Kidney Disease Epidemiology Collaboration (CKDEPI) equation. The plasma total L-homocysteine was measured
using a Fluorescence Polarization Immuno-assay on an Abbott
IMx Analyzer (Abbott Laboratories, Abbott Park, IL). The
interassay coefﬁcient of variation for homocysteine measurement was <5%. The total L-homocysteine includes free
monomeric homocysteine, free dimeric homocysteine, protein-bound forms, and mixed dimeric low molecular mass
forms.

Cardiac Disease Hospitalizations and Deaths
The ﬁrst episode of cardiac hospitalization or death was
identiﬁed using data from the Hospital Morbidity Data
Collection and WA Deaths Registry, linked via the Western
Australian Data Linkage System as described previously.11
DOI: 10.1161/JAHA.118.011028

Statistical Analysis
Baseline data are presented as either meanSD, median
and interquartile range (IQR), or number and (%) where
appropriate. Non-normally distributed baseline factors including NGAL were transformed using their natural logarithm (lnNGAL) to reduce skewness and improve approximation of
normal distribution. The associations between baseline
covariates on ln-NGAL were determined using univariate
linear regression analysis. Forward stepwise multivariable
regression analysis of variables signiﬁcant in the univariate
analysis was used to determine variables independently
associated with NGAL. As NGAL, homocysteine, and hs-TnI
were not normally distributed, Spearman’s correlations were
undertaken for unadjusted analyses. Unadjusted and multivariable-adjusted Cox proportional hazards regression analyses were undertaken to test the association of NGAL with
coronary heart disease (CHD) hospitalizations and deaths.
No violations of the Cox proportional hazards assumptions
were detected. Multivariable-adjustments included the variables used in the Framingham risk equation (model 1: age,
body mass index [BMI], current smoker, prescription of
antihypertensive medication, systolic blood pressure, history
of diabetes mellitus) plus treatment code (calcium or
placebo). Further analyses including replacing BMI with
Journal of the American Heart Association
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Table 1. Baseline Characteristics of the Cohort by Quartiles of NGAL
Baseline Characteristics

Whole Cohort (n=1131)

Quartile 1 (n=280)

Quartile 2 (n=284)

Quartile 3 (n=284)

Quartile 4 (n=283)

NGAL, median [IQR], ng/mL

76 [62–95]

54 [46–58]

69 [65–72]

85 [80–89]

113 [102–136]

†

†

75.82.8†

†

Age, meanSD, y

75.22.7

74.82.75

75.12.6

BMI, meanSD, kg/m2

27.04.7

25.74.3†

26.64.5†

27.04.3†

28.95.0†

Never, N (%)

708 (62.9)

175 (62.7)

181 (64.0)

175 (62.3)

177 (62.5)

Previous, N (%)

413 (36.7)

102 (36.6)

101 (35.7)

104 (37.0)

106 (37.5)

Current, N (%)

5 (0.4)

2 (0.7)

1 (0.4)

2 (0.7)

0 (0.0)

61 (5.4)

16 (5.7)

75.32.9

Smoking history

Diabetes mellitus, N (%)
Antihypertensive medication, N (%)

476 (42.1)

91 (32.5)

Statin medication, N (%)

186 (16.4)

44 (15.7)

Low-dose aspirin, N (%)

201 (17.8)

42 (15.0)

10 (3.5)
†

110 (38.7)

12 (4.2)
†

117 (41.2)

46 (16.2)

158 (55.8)†

47 (16.5)

46 (16.2)
†

23 (8.1)
†

49 (17.3)

58 (20.4)
†

55 (19.4)
†

1.1 [0.3–6.2]†

Alcohol intake, median [IQR], g/d

1.9 [0.3–10.1]

2.8 [0.3–11.9]

Exercise, median [IQR], h/wk

4.0 [1.0–7.0]

4.0 [2.0–7.0]†

4.0 [1.0–8.0]†

4.0 [0.3–7.0]†

3.0 [0.0–6.0]†

SBP, meanSD, mm Hg

13818

13818

13819

13719

13718

DBP, meanSD, mm Hg

7311

7312

7311

7311

7312

MAP, meanSD, mm Hg

9512

9512

9512

9412

9412

2.1 [0.3–11.3]

2.1 [0.3–10.0]

Blood pressure

Lipid profiles (n=807)

Downloaded from http://ahajournals.org by on January 14, 2019

Total cholesterol, meanSD, mg/dL

22743

22547

22540

23441

22542

LDLC, meanSD, mg/dL

14339

14041

14236

15038

14139

HDLC, meanSD, mg/dL

5615

6015†

5615†

5613†

5315†

Triglycerides, meanSD, mg/dL

13763

12356†

12960†

14162†

15470†

hs-cTnI, median [IQR], pg/mL

4.6 [3.6–6.1]

4.1 [3.4–5.4]†

4.4 [3.6–5.9]†

4.7 [3.7–6.4]†

5.1 [4.0–6.5]†

Homocysteine, median [IQR], lmol/L*

11.3 [9.3–13.5]

9.9 [8.5–12.1]†

10.7 [8.8–13.1]†

11.9 [9.8–14.2]†

12.5 [10.6–15.4]†

eGFR, meanSD, mL/min per 1.73 m2

66.313.0

72.310.6†

68.311.3†

64.312.6†

60.613.0†

Cardiovascular biomarkers

Results are meanSD or number and (%). BMI indicates body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular ﬁltration rate; HDLC, high-density lipoprotein
cholesterol; hs-cTnI, high-sensitivity cardiac troponin I; IQR, interquartile range; LDLC, low-density lipoprotein cholesterol; MAP, mean arterial pressure; NGAL, neutrophil gelatinaseassociated lipocalin; SBP, systolic blood pressure.
*Measured in 905 women.
†
Signiﬁcant across group differences using univariate ANOVA, x2 test or Kruskal-Wallis test where appropriate.

HDLC and total cholesterol (model 2) as well as further
adjustments for potential mediators of disease including
estimated glomerular ﬁltration rate (eGFR), hs-c-TnI, and
homocysteine were also undertaken. Additionally, given the
advanced age of these women, we also performed competing-risks analyses based on Fine and Gray’s proportional
subdistribution hazards model16 to account for the competing risk of noncardiac mortality (all-other causes of death).
The discriminative performance were calculated using the
Harrell’s C-statistic17 with discrimination considered to be
poor (<0.6), moderate (0.6–0.8), or good (≥0.8). Because of
the low sensitivity of these analyses, net reclassiﬁcation and
integrated discrimination improvement indices were also
DOI: 10.1161/JAHA.118.011028

performed.18 In order to do so, the ﬁrst model included all
the variables in the general Framingham risk model using
BMI and treatment code (referent model), and the second
model included all variables in the general Framingham
cardiovascular risk model using BMI plus treatment code
with the addition of NGAL (ln-NGAL, quartiles of NGAL, or
median NGAL). The calibration was tested by separating
participants into deciles of predicted risk compared with the
actual risk. For net reclassiﬁcation improvement, we used a
category-free approach (no P value applied) as there are no
suggested cut points for cardiovascular risk in the elderly.
All analyses were undertaken using IBM SPSS Statistics
Version 21 (2012, IBM Corp, Armonk, NY), STATA (version
Journal of the American Heart Association
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Results
Baseline Characteristics
Participant selection is outlined in Figure 1. To investigate the
associations and predictive utility of NGAL, we excluded these
114 individuals with prevalent CHD at baseline from all
subsequent analysis. NGAL levels were signiﬁcantly higher in
the excluded cohort of 114 women with prevalent CHD
compared with those included in the study cohort (82.3 [IQR
66.1–101.8] versus 75.9 [IQR 61.5–94.0], P=0.042). Baseline
characteristics of the remaining 1131 older women included
in the study are presented in Table 1.

Correlations Between Plasma NGAL and Baseline
Variables

Table 2. Correlations and Multivariate Associations Between
ln-NGAL, Clinical Variables, and Cardiac Biomarkers
Univariate Model

Multivariable Model

r

P Value

Standardized b

P Value

0.142

<0.001

0.104

0.004

BMI, kg/m

0.267

<0.001

0.213

<0.001

Diabetes mellitus
(yes)

0.069

0.021

Antihypertensive
medications (yes)

0.175

<0.001

Statin medications
(yes)

0.003

0.926

Low-dose aspirin
(yes)

0.046

0.120

Age, y
2

Systolic blood
pressure, mm Hg

0.030

0.327

Diastolic blood
pressure, mm Hg

0.016

0.604

Current smoking
(yes)

0.016

0.580

Downloaded from http://ahajournals.org by on January 14, 2019

The correlations between ln-NGAL levels and these demographic, clinical, lifestyle, and laboratory variables are shown in
Table 2. Using forward stepwise linear regression, the most
parsimonious model for ln-NGAL that explained 18.6% of the
circulating levels included eGFR (P<0.001), BMI (P<0.001), lnhomocysteine (P<0.001), age (P=0.004), and HDLC (P=0.016).

Total cholesterol,
mg/dL

Low-density
lipoprotein
cholesterol, mg/dL

0.030

NGAL Levels and CHD Events

Triglycerides, mg/dL

0.174

Over 14.5 years, 256/1131 (22.6%) women sustained CHD
hospitalization or death. For every 1 SD increase in ln-NGAL,
there was a 33% increase in the relative hazards for CHD
hospitalizations or death after adjusting for age and treatment
(hazard ratio [HR] 1.33, 95% CI 1.18–1.51, P<0.001). This
estimate remained similar after adjusting for conventional
cardiovascular risk factors used in the Framingham risk
equations (Table 3). Using a quartile approach, the relationship between baseline NGAL and CHD hospitalization and
death is shown in Figure 2, with the adjusted HR presented in
Table 4. Compared with those in the lowest quartile of NGAL,
those in the highest 2 quartiles had increased relative hazards
for CHD hospitalizations or deaths in unadjusted analysis and
multivariable-adjusted models. Similar results were seen
when replacing the BMI with total cholesterol and HDLC in
the subset of 807 women with these data available (Table 4).

eGFR, mL/min per
1.73 m2

NGAL Levels and Heart Failure Events
Over 14.5 years, 118/1131 (10.4%) women sustained HF
hospitalization or death. For every 1 SD increase in ln-NGAL,
there was a 30% increase in the relative hazards for HF
DOI: 10.1161/JAHA.118.011028

High-density
lipoprotein
cholesterol, mg/dL

0.025
0.157

0.320

0.470
<0.001

0.091

0.016

0.194

<0.001

0.401

<0.001
<0.001

Ln-high-sensitivity
cardiac troponin I

0.160

<0.001

Ln-homocysteine

0.284

<0.001

0.144

<0.001

Multivariable model r2=0.186. BMI indicates body mass index; eGFR, estimated
glomerular ﬁltration rate; NGAL, neutrophil gelatinase-associated lipocalin.

hospitalizations or death after adjusting for age and treatment
(HR 1.30, 95% CI 1.08–1.56, P=0.005), which was no longer
statistically signiﬁcant (P=0.060) after adjusting for conventional cardiovascular risk factors (Table 3). Using a quartile
approach, the relationship between baseline NGAL and HF
hospitalization and death is shown in Figure 2. The values for
the HRs are shown in Table 4. Compared with those in the
lowest quartile of NGAL, those in the fourth quartile had
increased relative hazards for HF hospitalizations or deaths in
unadjusted analysis but not in multivariable-adjusted models
(Table 4). Similar results were seen when replacing the BMI
with total cholesterol and HDLC in the subset of 807 women
with these data available (Table 4).
Journal of the American Heart Association
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Table 3. Multivariable-Adjusted HR for Cardiac Events Per SD Increase in the Natural Logarithm of Circulating NGAL
Coronary Heart Disease Events (n=256)

Heart Failure Event (n=118)

HR (95% CI)

P Value

HR (95% CI)

P Value

1.29 (1.13–1.48)

<0.001

1.21 (0.99–1.48)

0.060

+eGFR

1.25 (1.07–1.45)

0.004

1.30 (1.04–1.63)

0.019

+ln-hs-cTnI

1.27 (1.11–1.46)

0.001

1.18 (0.97–1.44)

0.106

+ln-homocysteine

1.21 (1.03–1.42)

0.027

1.11 (0.88–1.40)

0.379

+eGFR, ln-hs-cTnI,
and ln–homocysteine

1.21 (1.02–1.44)

0.032

1.17 (0.91–1.51)

0.232

1.49 (1.29–1.53)

<0.001

1.22 (0.98–1.52)

0.076

+eGFR

1.37 (1.16–1.62)

<0.001

1.26 (0.98–1.61)

0.066

+ln-hs-cTnI

1.40(1.20–1.64)

<0.001

1.45 (1.20–1.74)

0.133

+ln-homocysteine

1.35 (1.13–1.62)

0.001

1.14 (0.54–2.72)

0.305

+eGFR, ln-hs-cTnI and
ln-homocysteine

1.34 (1.11–1.62)

0.003

1.17 (0.89–1.54)

0.249

Model 1 (n=1131)*

Model 2 (n=807)†

Cox proportional hazard regression models were adjusted for conventional cardiovascular risk factors (Model 1 including; age, BMI, current smoking, systolic blood pressure,
prescription of antihypertensive medications, diabetes mellitus, and treatment code [calcium or placebo] or Model 2 including; age, total cholesterol, high-density lipoprotein
cholesterol, current smoking, systolic blood pressure, prescription of antihypertensive medications, diabetes mellitus, and treatment code [calcium or placebo]). BMI
indicates body mass index; eGFR, estimated glomerular ﬁltration rate; HR, hazard ratio; hs-cTnI, high-sensitivity cardiac troponin I; NGAL, neutrophil gelatinase-associated
lipocalin.
*Homocysteine was measured in 905 women.
†
Homocysteine was measured in 700 women.

NGAL Levels and Cardiac Risk Prediction
Downloaded from http://ahajournals.org by on January 14, 2019

As circulating NGAL levels were not associated with HF events
in multivariable-adjusted models, no further analyses were

performed to determine whether the addition of NGAL improved
risk prediction in addition to conventional risk factors. To study
the effects of NGAL as a risk predictor for CHD, we compared it
individually with conventional risk factors used in the

Figure 2. Kaplan–Meier hazard plots for CHD (n=256) and HF hospitalizations and deaths (n=118) by quartiles of NGAL, blue line quartile 1
(<61.5 ng/mL), green line quartile 2 (61.5–75.8 ng/mL), beige line quartile 3 (75.9–94.8 ng/mL), and purple line quartile 4 (≥94.9 ng/mL).
CHD indicates coronary heart disease; HF, heart failure; NGAL, neutrophil gelatinase-associated lipocalin.

DOI: 10.1161/JAHA.118.011028
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Table 4. Multivariable-Adjusted HR for Cardiac Events by Quartile of NGAL After Adjustment of Other Risk Factors

Number of Events (%)

Model 1*
HR (95% CI)

P Value

Model 2*
HR (95% CI)

P Value

Whole cohort (n=1131)
CHD events (n=256)
Quartile 1 (<61.5 ng/mL)

44 (15.7)

1.00 (referent)

Quartile 2 (61.5–75.8 ng/mL)

48 (16.9)

1.02 (0.68–1.54)

0.909

1.03 (0.67–1.59)

0.887

Quartile 3 (75.9–94.8 ng/mL)

72 (25.4)

1.62 (1.11–2.35)

0.012

1.61 (1.08–2.39)

0.019

Quartile 4 (≥94.9 ng/mL)

92 (32.5)

2.14 (1.49–3.08)

<0.001

1.97 (1.33–2.93)

0.001

P for trend

1.00 (referent)

<0.001

<0.001

1.00 (referent)

1.00 (referent)

Heart failure events (n=118)
Quartile 1 (<61.5 ng/mL)

22 (7.9)

Quartile 2 (61.5–75.8 ng/mL)

27 (9.5)

1.13 (0.65–1.99)

0.664

1.22 (0.66–1.91)

0.528

Quartile 3 (75.9–94.8 ng/mL)

24 (8.5)

1.01 (0.57–1.81)

0.971

1.01 (0.54–1.88)

0.985

Quartile 4 (≥94.9 ng/mL)

61 (15.9)

1.97 (1.17–3.30)

0.002

1.65 (0.92–2.96)

0.093

P for trend

0.004

0.079

1.00 (referent)

1.00 (referent)

Those with lipids (n=807)
CHD events (n=170)
Quartile 1 (<61.5 ng/mL)

24 (12.0)

Quartile 2 (61.5–75.8 ng/mL)

32 (15.2)

1.23 (0.71–1.60)

0.442

1.28 (0.73–2.23)

0.384

Quartile 3 (75.9–94.8 ng/mL)

52 (25.2)

2.16 (1.33–3.50)

0.002

2.15 (1.29–3.58)

0.003

Quartile 4 (≥94.9 ng/mL)

62 (32.6)

2.81 (1.75–4.52)

<0.001

2.64 (1.59–4.38)

<0.001

P for trend
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<0.001

<0.001

1.00 (referent)

1.00 (referent)

Heart failure events (n=83)
Quartile 1 (<61.5 ng/mL)

15 (7.5)

Quartile 2 (61.5–75.8 ng/mL)

20 (9.5)

1.18 (0.61–2.31)

0.624

1.28 (0.63–2.60)

0.494

Quartile 3 (75.9–94.8 ng/mL)

19 (9.2)

1.16 (0.59–2.28)

0.669

1.31 (0.64–2.66)

0.462

Quartile 4 (≥94.9 ng/mL)

29 (15.3)

1.88 (1.00–3.53)

0.049

1.63 (0.82–3.23)

0.161

P for trend

0.034

0.167

CHD indicates coronary heart disease; HR, hazard ratio; NGAL, neutrophil gelatinase-associated lipocalin.
*Cox regression models were adjusted for conventional cardiovascular risk factors (Model 1 including age, and treatment code [calcium or placebo] or Model 2 including age, BMI or total
cholesterol and high-density lipoprotein cholesterol, current smoking, systolic blood pressure, prescription of antihypertensive medications, diabetes mellitus, and treatment code [calcium
or placebo]).

Framingham Risk Score (Table 5). Ln-NGAL alone had poor
discrimination quantiﬁed by the area under the receiver
operating characteristic curve (c-statistic) for CHD (0.594,
95% CI 0.558–0.629). The addition of NGAL did not improve the
C-statistic for 14.5-year cardiac events compared with conventional cardiovascular risk factors. However, newer measures of discrimination such as the Net Reclassiﬁcation Index
and the Integrated Discrimination Index suggested that the
addition of NGAL may lead to substantial improvements. This
was particularly evident in models incorporating HDLC and total
cholesterol, with large proportions of women having a CHD
event moved correctly up in risk and women who did not sustain
a CHD event moved down in risk (Table 5).
DOI: 10.1161/JAHA.118.011028

Putative Pathophysiological Mechanisms of NGAL
With Cardiac Outcomes
Given the lack of information on the mechanisms of adverse
effects of circulating NGAL on coronary atherosclerosis, we
sought to investigate whether NGAL was acting as a surrogate
marker of kidney function (eGFR), cardiac inﬂammation (homocysteine), and myocardial ischemia (hs-cTnI) or was independent
of these markers of cardiovascular disease by including these
biomarkers individually or collectively into the multivariableadjusted models (Table 6). The Kaplan–Meier hazard plots for
CHD and HF hospitalizations and deaths separated by above and
below the median NGAL and hs-cTnI are presented in Figure 3.
Journal of the American Heart Association
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Table 5. Area Under the Curve, NRI, and IDI

c-Statistic

P Value*

Category Free
NRI (95% CI)

Correctly
Reclassiﬁed
Higher (%)

Correctly
Reclassiﬁed
Lower (%)

IDI

P Value*

Model 1 (n=1131)
CHD events (n=256)
Conventional risk factors

0.625

+ln-NGAL

0.637

0.175

0.258

14.9

11.0

0.013

<0.001

+Quartiles of NGAL

0.641

0.135

0.329

23.2

9.8

0.017

<0.001

+Above the median NGAL

0.639

0.146

0.371

30.6

6.5

0.015

<0.001

Model 2 (n=807)
CHD events (n=170)
Conventional risk factors

0.637

+ln-NGAL

0.660

0.064

0.366

18.3

18.3

0.029

<0.001

+Quartiles of NGAL

0.662

0.078

0.451

31.7

13.4

0.029

<0.001

+Above the median NGAL

0.658

0.149

0.471

36.6

10.5

0.027

<0.001

BMI indicates body mass index; CHD, coronary heart disease; IDI, integrated discrimination improvement; NGAL, neutrophil gelatinase-associated lipocalin; NRI, net reclassiﬁcation
improvement.
*Compared with conventional risk factors (Model 1 including age, BMI, current smoking, systolic blood pressure, prescription of antihypertensive medications, diabetes mellitus, and
treatment code [calcium or placebo] or Model 2 including age, total cholesterol, high-density lipoprotein cholesterol, current smoking, systolic blood pressure, prescription of
antihypertensive medications, diabetes mellitus, and treatment code [calcium or placebo]).

For all analyses with the CHD outcome with the biomarkers
individually and NGAL, both remained signiﬁcantly associated
with CHD outcomes. When all 3 biomarkers were added, NGAL
remained signiﬁcantly associated with CHD events.
Downloaded from http://ahajournals.org by on January 14, 2019

Further Analyses
Interaction testing between NGAL and cardiovascular risk factors
for CHD events is presented in Table 7. This testing suggested that
NGAL may be more strongly associated with CHD events when
HDLC is normal. To explore the extent of reverse causality bias, we
excluded cardiac events occurring within the ﬁrst 2 years as well
as undertaking competing risks regression analyses with deaths
as a competing risk, both of which did not substantially alter the
ﬁndings (Table 8). Additionally, we tested the association of NGAL
with myocardial infarctions and/or CHD death (hard CHD) that
occurred in 172/1131 (15.2%) of the women. Per SD increase in
ln-NGAL was associated with increased relative hazards of hard
CHD (unadjusted HR 1.39, 95% CI 1.20–1.61, P<0.001 and
multivariable-adjusted HR 1.30, 95% CI 1.10–1.53, P=0.002).
Similarly, in the quartile analysis, women in the highest quartile of
NGAL had the highest relative hazards of hard CHD (quartile 4
versus quartile 1 unadjusted HR 2.28, 95% CI 1.49–3.50, P<0.001
and multivariable-adjusted HR 1.84, 95% CI 1.16–2.94, P=0.010).

Discussion
To our knowledge, this is the ﬁrst prospective study to investigate
the associations between plasma NGAL and the cardiac ischemia
DOI: 10.1161/JAHA.118.011028

biomarker hs-cTnI. Additionally, we investigated NGAL as a
predictor of CHD and HF in older women with no previous clinical
CHD. Higher levels of plasma NGAL were independently
associated with a worse CHD risk proﬁle, elevated levels of hscTnI and homocysteine, and a 2- to 3-fold increase in the relative
hazards for CHD hospitalizations and death in the highest
quartile of NGAL women compared with those in the lowest
quartile. These ﬁndings are consistent with other prospective
cohort studies in middle-aged19 and older community-dwelling
adults20 that have shown independent associations between
NGAL and CHD events. These associations were robust and
independent of hs-TnI, homocysteine, and eGFR. To our knowledge, this is the ﬁrst study to show that NGAL is associated with
CHD events, independent of hs-TnI.
All women had detectable NGAL, with levels correlating
with hs-cTnI. Cardiac troponin levels are now the standard of
care to identify myocyte necrosis and for cardiovascular risk
stratiﬁcation. Serum cardiac troponin levels directly relate to
the risk of future cardiovascular events in both young and
elderly populations and improve risk prediction in addition to
current established risk factors.11,21 Therefore, the establishment of NGAL as a novel biomarker with added predictive
value above and beyond cardiac troponins has implications for
provision of cardiovascular care and associated health costs.
Similarly, NGAL levels correlated with homocysteine concentrations (r=0.3, P<0.001), supporting a previous report in a
small cohort of 141 patients who had advanced carotid
atherosclerotic lesions and who underwent carotid
endarterectomy for vascular repair, r=0.4, P<0.001.22 Taken
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Table 6. Multivariable-Adjusted HR for Coronary Events by NGAL and Biomarkers of Potential Pathological Mechanisms*

Number of Events (%)

Model 1*
HR (95% CI)

↓NGAL and ↓hs-cTnI, n=319/229

42 (13.2)

1.00 (referent)

P Value

Number of Events (%)

Model 2*
HR (95% CI)

23 (10.0)

1.00 (referent)

P Value

NGAL and hs-cTnI
↓NGAL and ↑hs-cTnI, n=239/171

49 (20.5)

1.57 (1.01–2.43)

0.043

31 (19.3)

1.92 (1.09–3.37)

0.026

↑NGAL and ↓hs-cTnI, n=240/177

49 (20.4)

1.51 (0.97–2.35)

0.069

32 (18.1)

1.76 (0.99–3.15)

0.056

↑NGAL and ↑hs-cTnI, n=322/219

115 (35.7)

2.72 (1.84–4.03)

<0.001

81 (37.0)

3.73 (2.24–6.22)

<0.001

↓NGAL and ↓homocysteine, n=273/216

39 (14.3)

1.00 (referent)

30 (13.2)

1.00 (referent)

↓NGAL and ↑homocysteine, n=175/138

32 (18.3)

1.25 (0.77–2.03)

0.365

19 (13.8)

0.85 (0.46–1.56)

0.602

↑NGAL and ↓homocysteine, n=172/135

38 (22.1)

1.47 (0.92–2.34)

0.104

30 (22.4)

1.56 (0.93–2.63)

0.095

↑NGAL and ↑homocysteine, n=285/211

88 (30.9)

1.97 (1.32–2.94)

0.001

64 (30.3)

1.85 (1.17–2.95)

0.009

↓NGAL and no CKD, n=403/306

61 (15.1)

1.00 (referent)

38 (12.4)

1.00 (referent)

↓NGAL and CKD, n=100/80

22 (22.0)

1.54 (0.92–2.59)

0.102

16 (20.0)

1.56 (0.84–2.90)

0.161

↑NGAL and no CKD, n=290/205

66 (22.8)

1.57 (1.09–2.24)

0.014

45 (22.0)

1.78 (1.15–2.77)

0.010

↑NGAL and CKD, n=223/165

88 (39.5)

2.99 (2.14–4.18)

<0.001

89 (39.4)

3.22 (2.11–4.92)

<0.001

NGAL and homocysteine

NGAL and chronic kidney disease

*Cox regression models were adjusted for conventional cardiovascular risk factors (Model 1 including age, and treatment code [calcium or placebo] or Model 2 including age, total
cholesterol, high-density lipoprotein cholesterol, current smoking, systolic blood pressure, prescription of antihypertensive medications, diabetes mellitus, and treatment code [calcium or
placebo]). ↓=Less than the median value and ↑ greater than or equal to the median value. CKD indicates chronic kidney disease; HR, hazard ratio; hs-cTnI, high-sensitivity cardiac troponin I;
NGAL, neutrophil gelatinase-associated lipocalin.
*Homocysteine only measured in 905 women.
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together, these ﬁndings suggest that a relationship between
NGAL and homocysteine exists and warrants further study.
While the women in our study did not have pre-existing
clinical CHD at baseline, NGAL was associated with several

traditional cardiovascular risk factors including age, hypertension, renal impairment, and low HDL levels. Similar
ﬁndings were reported by Elneihoum et al,23 where plasma
levels of NGAL were higher in older hypertensive women

Figure 3. Kaplan–Meier hazard plots for CHD (n=256) and HF hospitalizations and deaths (n=118) by ↑ or ↓ median NGAL and ↑ or ↓ median

hs-TnI. Blue line=↓ median NGAL and ↓ median hs-TnI, green line=↑ median NGAL and ↓ median hs-TnI, beige line=↓ median NGAL and ↑ median
hs-TnI and purple line=↑ median NGAL and ↑ median hs-TnI. CHD indicates coronary heart disease; HF, heart failure; hs-TnI, high-sensitivity
cardiac troponin I; NGAL, neutrophil gelatinase-associated lipocalin.
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Table 7. Age-Adjusted HR for CHD Events Per SD Increase in
ln-NGAL

Table 7. Continued
Coronary Heart Disease Events

Coronary Heart Disease Events

N (%)

HR (95% CI), P Value*

P Value
Inter.

<20% (n=577)

100 (17)

1.21 (0.98–1.49), 0.079

0.268

≥20% (n=513)

142 (28)

1.41 (1.20–1.65), <0.001

<75 y (n=515)

100 (19)

1.38 (1.13–1.69), 0.002

≥75 y (n=616)

156 (25)

1.31 (1.12–1.53), 0.001

<25 kg/m2 (n=401)

80 (20)

1.29 (0.98–1.69), 0.067

25–29 kg/m2 (n=473)

102 (22)

1.45 (1.20–1.75), <0.001

≥30 kg/m2 (n=255)

74 (29)

1.12 (0.90–1.39), 0.317

Framingham risk scores

Age, y
0.788

BMI

82 (17)

1.08 (0.85–1.37), 0.548

Yes (n=635)

174 (27)

1.38 (1.20–1.59), <0.001

<200 mg/dL (n=194)

35 (18)

1.27 (0.93–1.74), 0.137

≥200 mg/dL (n=613)

135 (22)

1.57 (1.31–1.83), <0.001

<60 mg/dL (n=514)

123 (24)

1.64 (1.37–1.95), <0.001

≥60 mg/dL (n=293)

47 (16)

1.14 (0.86–1.51), 0.360

Never (n=708)

143 (20)

1.29 (1.09–1.53), 0.003

Yes (n=418)

112 (27)

1.36 (1.14–1.64), 0.001

No (n=1070)

238 (22)

1.34 (1.17–1.52), <0.001

Yes (n=61)

18 (30)

1.16 (0.78–1.73), 0.459

No (n=945)

214 (23)

1.32 (1.15–1.50), <0.001

Yes (n=186)

42 (23)

1.44 (1.02–2.04), 0.038

No (n=930)

200 (22)

1.35 (1.17–1.56), <0.001

Yes (n=201)

56 (28)

1.26 (0.98–1.61), 0.072

<median (n=538)

127 (24)

1.29 (1.09–1.53), 0.004

≥median (n=593)

129 (22)

1.37 (1.15–1.64), <0.001

0.101

Elevated total cholesterol
0.248

Low HDLC
0.030

Smoking history
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0.837

History of diabetes mellitus
0.830

Lipid-lowering therapy
0.091

Low-dose aspirin
0.523

Physical activity
0.514

eGFR <60 mL/min per 1.73 m2
Yes (n=323)

110 (34)

1.33 (1.10–1.61), 0.003

No (n=694)

127 (18)

1.18 (0.97–1.43), 0.085

<median (n=558)

91 (16)

1.38 (1.11–1.70), 0.004

≥median (n=562)

164 (29)

1.24 (1.06–1.44), 0.006

0.446

hs-cTnI
0.442

Continued

DOI: 10.1161/JAHA.118.011028

HR (95% CI), P Value*

P Value
Inter.

<median (n=445)

77 (17)

1.26 (0.99–1.61), 0.061

0.829

≥median (n=460)

120 (26)

1.30 (1.08–1.56), 0.005

Homocysteine†

BMI indicates body mass index; eGFR, estimated glomerular ﬁltration rate; HDLC, highdensity lipoprotein cholesterol; HR, hazard ratio; hs-cTnI, high-sensitivity cardiac troponin
I; NGAL, neutrophil gelatinase-associated lipocalin.
*P value from age and treatment (calcium or placebo)-adjusted Cox regression. P value
per inter. from the interaction between per SD increase in ln-NGAL with baseline
variables with signiﬁcance set at (P<0.1).
†
Homocysteine was measured in a subset of 905 women.

0.479

Hypertension
No (n=496)

N (%)

compared with younger normotensive individuals. We and
others have demonstrated the relationship between increased
circulating NGAL and high creatinine/reduced eGFR.24 In the
present study, the strongest relationship between NGAL and
CHD risk was seen in women with established cardiovascular
risk factors, suggesting that plasma NGAL provides additive
predictive value above cardiac troponin I in women at the
highest risk. This is demonstrated in Figure 3, showing that
women with elevated NGAL but not hs-TnI and vice versa had
similar long-term prognosis while women with elevated levels
of both had the highest CHD risk. Given that hs-cTnIs are
emerging as valuable markers of long-term cardiovascular risk
in people without a history of cardiovascular disease,25 these
ﬁndings are particularly noteworthy.
Regarding determination of clinical limits for NGAL levels
and associated cardiovascular risk assessment, there are
published reports using a variety of in-house or commercial
assays for quantiﬁcation,20,26–28 but the agreement between
these assays and the speciﬁcity of these assays to detect
different circulating forms remains to be demonstrated. Given
these issues, we used 3 different models based on the
distribution with Framingham risk scores plus ln-NGAL (continuous), median NGAL, and quartiles of NGAL to provide similar
data to previous studies investigating broader composite
cardiovascular disease events or deaths.19,20 Similar to these
studies, we found modest improvements to the c-statistic;
however, in our study these were nonsigniﬁcant, presumably
because of the smaller sample size and fewer events. We did,
however, see relatively large improvements to reclassiﬁcation
with the addition of NGAL to Framingham risk scores. The
discrepancy between the ﬁndings for the c-statistic and the net
reclassiﬁcation may reﬂect previous observations that the use
of receiver operating characteristic may be less sensitive and
less clinically relevant than reclassiﬁcation indices.29,30
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SHR (95% CI)*

P Value

Whole cohort (n=1131)
CHD events (n=256)
Quartile 1 (<61.5 ng/mL)

1.00 (referent)

Quartile 2 (61.5–75.8 ng/mL)

1.03 (0.67–1.59)

0.887

Quartile 3 (75.9–94.8 ng/mL)

1.61 (1.08–2.39)

0.019

Quartile 4 (≥94.9 ng/mL)

1.97 (1.33–2.93)

0.001

Heart failure events (n=118)
Quartile 1 (<61.5 ng/mL)

1.00 (referent)

Quartile 2 (61.5–75.8 ng/mL)

1.22 (0.66–1.91)

0.528

Quartile 3 (75.9–94.8 ng/mL)

1.01 (0.54–1.88)

0.985

Quartile 4 (≥94.9 ng/mL)

1.65 (0.92–2.96)

0.093

Those with lipids (n=807)
CHD events (n=170)
Quartile 1 (<61.5 ng/mL)

1.00 (referent)

Quartile 2 (61.5–75.8 ng/mL)

1.28 (0.73–2.23)

0.384

Quartile 3 (75.9–94.8 ng/mL)

2.15 (1.29–3.58)

0.003

Quartile 4 (≥94.9 ng/mL)

2.64 (1.59–4.38)

<0.001

Heart failure events (n=83)
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Quartile 1 (<61.5 ng/mL)

1.00 (referent)

Quartile 2 (61.5–75.8 ng/mL)

1.28 (0.63–2.60)

0.494

Quartile 3 (75.9–94.8 ng/mL)

1.31 (0.64–2.66)

0.462

Quartile 4 (≥94.9 ng/mL)

1.63 (0.82–3.23)

0.161

BMI indicates body mass index; CHD, coronary heart disease; NGAL, neutrophil
gelatinase-associated lipocalin; SHR, subdistribution hazard ratio.
*Models were adjusted for conventional cardiovascular risk factors (Model 1 including
age, BMI, current smoking, systolic blood pressure, prescription of antihypertensive
medications, diabetes mellitus, and treatment code [calcium or placebo] or Model 2
including age, total cholesterol, high-density lipoprotein cholesterol, current smoking,
systolic blood pressure, prescription of antihypertensive medications, diabetes mellitus;
and treatment code [calcium or placebo]).

Circulating NGAL has been related to local production in
many tissues and thus may reﬂect local tissue inﬂammation.
To date the majority of human studies investigating the
association of circulating NGAL with heart disease have been
cross-sectional studies, in patients with pre-existing disease.
Such studies make causality harder to infer. Importantly,
these studies do suggest that NGAL may be related to the
presence and severity of CAD.3,23,27,31 Indeed, 2 prospective
studies of patients undergoing cardiac surgery for CAD have
shown that pre/postoperative plasma NGAL is independently
associated with all-cause mortality,28 cardiovascular deaths,
or subsequent cardiac events.26 In a prospective study of
younger men and women without a history of clinical
cardiovascular disease, plasma NGAL was independently
associated with 10-year cardiovascular outcomes and
DOI: 10.1161/JAHA.118.011028

modestly improved the c-statistic and net reclassiﬁcation
when added to the Framingham risk scores.19 Daniels et al20
followed elderly men and women without a history of clinical
cardiovascular disease for a maximum of 16.2 years and
found that plasma NGAL was independently associated with
a composite end point of myocardial infarction, revascularization, or cardiovascular disease death, providing incremental value to the well-established biomarkers N-terminal probrain natriuretic peptide and C-reactive protein. It is
reassuring that the adjusted HR for the composite outcome
(HR 1.33) in this study was very similar to that seen in this
cohort (HR 1.29), suggesting that these ﬁndings may be
generalizable to other similarly aged populations. However,
before this present study, the association of NGAL with
markers of ongoing CAD, plaque rupture, or myocyte damage
(such as with cardiac troponin elevation) has not been
investigated.
The recent CANTOS trial showed that a human monoclonal
antibody targeting interleukin-1b lowered rates of recurrent
cardiovascular events in patients with myocardial infarction
and elevated high-sensitivity C-reactive protein, independent
of low-density lipoprotein cholesterol lowering.32 This has
reinvigorated discussions on direct roles for chronic inﬂammation in CAD. Similarly, there may be a chronic inﬂammatory
role for NGAL. Indeed, NGAL is induced by interleukin-1b in
murine adipocytes,33 human hepatic stellate cells and
hepatocytes,34 vascular smooth muscle cells,35 and isolated
neonatal rat cardiomyocytes.36 Signiﬁcantly, one study has
reported a close association between NGAL and highsensitivity C-reactive protein, with concomitant reductions in
both high-sensitivity C-reactive protein ( 40%) and NGAL
( 32%) following 8-week treatment with rosiglitazone,8 an
insulin-sensitizer with interleukin-1b antagonism effects.37,38
However, it should be noted that this study was nonrandomized and had no control group as well as a limited sample size.
Therefore, further investigations are needed in this area.
Aside from the role of NGAL in inﬂammation, studies
suggest that NGAL is involved in iron homeostasis. Given that
iron overload and deﬁciencies have been associated with
impaired cardiac function and hypercoagulation, NGAL may
therefore play a key role in development of certain cardiomyopathies. In addition, NGAL may play a role in regulating
aldosterone-mediated hypertension, with genetic inactivation
of NGAL in mice preventing mineralocorticoid-induced blood
pressure increases. Furthermore, in vitro studies suggest that
NGAL may inﬂuence the proliferation of ﬁbroblasts. Given a
key role of proliferation, particularly by myoﬁbroblasts, in the
mechanisms of remodeling, the proliferative effects of NGAL
may also be involved in pathological cardiac remodeling.
With an aging population, the proportion of elderly patients
undergoing percutaneous coronary intervention has increased
considerably.39 The elderly are also at higher risk for
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(Noncardiac Deaths) for Cardiac Events Per Quartile of NGAL
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Conclusions
In conclusion, we have demonstrated that circulating NGAL is
independently associated with long-term CHD outcomes in
older women and may improve risk prediction in high-risk
older women.
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